Cordyceps Sinensis Relieves Non-small Cell Lung Cancer by Inhibiting the MAPK Pathway

Overview

Journal Chin Med

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2024 Mar 26

PMID 38528546

Authors

Tianming Lu

Lirun Zhou

Zheng Chu

Yang Song

Qixin Wang

Minghong Zhao

Chuanhao Dai

Lin Chen

Guangqing Cheng

Jigang Wang

Qiuyan Guo

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the pharmacodynamic mechanism underlying Cordyceps sinensis relief in a murine model of non-small cell lung cancer (NSCLC).

Methods: We created a murine model of NSCLC and studied the potential molecular mechanism by which C. sinensis relieved NSCLC using a combination of transcriptomics, proteomics, and experimental validation.

Results: C. sinensis markedly suppressed the fluorescence values in mice with NSCLC, improved the pathologic morphology of lung tissue, ameliorated inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-10, and the oxidative stress indicators superoxide dismutase, malondialdehyde, and glutathione peroxidase). Transcriptomics results showed that the therapeutic effect of C. sinensis was primarily involved in the differentiation and activation of T cells. Based on the proteomic results, C. sinensis likely exerted a protective effect by recruiting immune cells and suppressing tumor cell proliferation via the MAPK pathway. Finally, the experimental validation results indicated that C. sinensis significantly decreased the VEGF and Ki67 expression, downregulated RhoA, Raf-1, and c-fos expression, which are related to cell migration and invasion, increased the serum concentration of hematopoietic factors (EPO and GM-CSF), and improved the percentage of immune cells (natural killer cells, dendritic cells, and CD4 and CD8 lymphocytes), which enhanced immune function.

Conclusions: Based on our preclinical study, C. sinensis was shown to exert a protective effect on NSCLC, primarily by inhibiting the MAPK pathway.

Citing Articles

Uncovering proteome variations and concomitant quality changes of different drying methods by 4D-DIA structural proteomics.

Xiao M, Tang C, Wang T, He M, Li Y, Li X Front Nutr. 2025; 12:1463780.

PMID: 39973924 PMC: 11835701. DOI: 10.3389/fnut.2025.1463780.

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.

Efficacy of traditional Chinese medicine as an adjunctive treatment in patients with renal dysfunction: a systematic-review and meta-analysis.

Wu F, Xu C, Si X, He F, Xu K, Zhang Y Front Med (Lausanne). 2025; 11():1477569.

PMID: 39839641 PMC: 11747039. DOI: 10.3389/fmed.2024.1477569.

Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.

Ma G, Jin Y Pharm Biol. 2024; 62(1):803-817.

PMID: 39460586 PMC: 11514402. DOI: 10.1080/13880209.2024.2415643.

References

Jakobsen J, Sorensen J . Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2012; 79(1):1-7. DOI: 10.1016/j.lungcan.2012.10.008. View

Hicklin D, Ellis L . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2004; 23(5):1011-27. DOI: 10.1200/JCO.2005.06.081. View

Xu H, Li S . [Pharmacological effects of Bailing capsule and its application in lung disease research]. Zhongguo Zhong Yao Za Zhi. 2011; 35(20):2777-81. View

Lai Y, Shen Y, Liu X, Zhang Y, Zeng Y, Liu Y . Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-kinase-Rac1/RhoA pathway. Int J Biol Sci. 2011; 7(6):782-91. PMC: 3133886. DOI: 10.7150/ijbs.7.782. View

Khiem D, Cyster J, Schwarz J, Black B . A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc Natl Acad Sci U S A. 2008; 105(44):17067-72. PMC: 2579379. DOI: 10.1073/pnas.0804868105. View

Wang X, Tang P, Guo F, Zhang M, Chen Y, Yan Y . RhoA regulates Activin B-induced stress fiber formation and migration of bone marrow-derived mesenchymal stromal cell through distinct signaling. Biochim Biophys Acta Gen Subj. 2016; 1861(1 Pt A):3011-3018. DOI: 10.1016/j.bbagen.2016.09.027. View

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

Bros M, Haas K, Moll L, Grabbe S . RhoA as a Key Regulator of Innate and Adaptive Immunity. Cells. 2019; 8(7). PMC: 6678964. DOI: 10.3390/cells8070733. View

Wang J, Li R, Wang W, Pan H, Xie C, Yau L . CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8Tim3 exhausted T cells in non-small cell lung cancer. Pharmacol Res. 2023; 194:106850. DOI: 10.1016/j.phrs.2023.106850. View

10.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

11.

Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J . T lymphocyte cell: A pivotal player in lung cancer. Front Immunol. 2023; 14:1102778. PMC: 9911803. DOI: 10.3389/fimmu.2023.1102778. View

12.

Chen J, Chen Y, Yang S, Ko Y, Chen S . Immunological alterations in lupus-prone autoimmune (NZB/NZW) F1 mice by mycelia Chinese medicinal fungus Cordyceps sinensis-induced redistributions of peripheral mononuclear T lymphocytes. Clin Exp Med. 2009; 9(4):277-84. DOI: 10.1007/s10238-009-0043-3. View

13.

Chu J, Hu X, Li C, Li T, Fan H, Jiang G . KLF14 alleviated breast cancer invasion and M2 macrophages polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling. Cell Signal. 2022; 92:110242. DOI: 10.1016/j.cellsig.2022.110242. View

14.

Ridley A . RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc. 2013; 251(3):242-9. DOI: 10.1111/jmi.12025. View

15.

Zhang J, Lei W, Chen X, Wang S, Qian W . Oxidative stress response induced by chemotherapy in leukemia treatment. Mol Clin Oncol. 2018; 8(3):391-399. PMC: 5867396. DOI: 10.3892/mco.2018.1549. View

16.

Pradhan R, Singhvi G, Dubey S, Gupta G, Dua K . MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. Future Med Chem. 2019; 11(8):793-795. DOI: 10.4155/fmc-2018-0468. View

17.

Liao X, Tao L, Guo W, Wu Z, Du H, Wang J . Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Front Oncol. 2020; 10:1732. PMC: 7505117. DOI: 10.3389/fonc.2020.01732. View

18.

Li K, Cheng H, Shen W, Leung E, Le S, Yu L . Compound Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2021; 2021:9535061. PMC: 8702306. DOI: 10.1155/2021/9535061. View

19.

Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View

20.

Shashidhar M, Giridhar P, Udaya Sankar K, Manohar B . Bioactive principles from : A potent food supplement - A review. J Funct Foods. 2020; 5(3):1013-1030. PMC: 7104994. DOI: 10.1016/j.jff.2013.04.018. View